Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Osteoporosis 1 Multiple Myeloma 1 Hematologic Neoplasms 1 Esophageal Neoplasms 1 Carcinoma, Squamous Cell 1 Breast Neoplasms 1 Bone Diseases, Metabolic 1 Adenocarcinoma 1

Interventions

Dexamethasone 277 Lenalidomide 155 Bortezomib 152 Cyclophosphamide 115 Melphalan 107 Calcium Dobesilate 107 fludarabine phosphate 70 carfilzomib 61 pomalidomide 55 Peripheral Blood Stem Cell Transplantation 53 Whole-Body Irradiation 52 Mycophenolic Acid 52 Granulocyte Colony-Stimulating Factor 52 Filgrastim 52 daratumumab 46 fludarabine 43 Tacrolimus 41 ixazomib 40 Busulfan 40 Thalidomide 36 Cyclosporine 32 dexamethasone acetate 26 Stem Cell Transplantation 26 Antilymphocyte Serum 25 dexamethasone 21-phosphate 22 plerixafor 20 auricularum 20 belantamab mafodotin 19 Prednisone 19 Etoposide 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Multiple Myeloma × Ibandronic Acid × Clear all

NCT02739594 2016-07-22

COMPARE

Hoffmann-La Roche

Phase 3 Terminated

89 enrolled 17 charts

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡